Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma

This publication has 11 references indexed in Scilit:

• WT1 expression level and clinical factors in multiple myeloma.
  2005
• Selective infiltration of CCR5⁺CXCR3⁺ T lymphocytes in human colorectal carcinoma
  International Journal of Cancer, 2005
• Myeloma Cells Are Highly Sensitive to the Granule Exocytosis Pathway Mediated by WT1-Specific Cytotoxic T Lymphocytes
  Clinical Cancer Research, 2004
• Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
  Proceedings of the National Academy of Sciences, 2004
• Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation
  Journal of Immunological Methods, 2003
• CXCR4–SDF-1 Signalling, Locomotion, Chemotaxis and Adhesion
  Journal of Molecular Histology, 2003
• Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues
  Cancer Immunology, Immunotherapy, 2002
• Wilms’ Tumor GeneWT1: Its Oncogenic Function and Clinical Application
  International Journal of Hematology, 2001
• Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth
  Japanese Journal of Cancer Research, 1999
• Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
  Cell, 1990